Bristol-Myers Squibb Company (NYSE:BMY) saw some unusual options trading on Thursday. Traders acquired 47,415 call options on the company. This is an increase of approximately 418% compared to the typical daily volume of 9,159 call options.

Several analysts recently commented on BMY shares. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 price objective on the stock in a research note on Wednesday, July 12th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. BMO Capital Markets reaffirmed an “underperform” rating and set a $47.00 price objective (down previously from $51.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, July 26th. BidaskClub raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Finally, Leerink Swann dropped their price objective on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a research note on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $62.31.

Bristol-Myers Squibb (NYSE BMY) opened at 59.90 on Friday. The company has a market cap of $98.23 billion, a PE ratio of 21.88 and a beta of 1.18. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $60.75. The stock has a 50 day moving average price of $56.77 and a 200 day moving average price of $55.51.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the business posted $0.69 EPS. The firm’s revenue was up 5.6% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb will post $2.98 EPS for the current fiscal year.

In related news, Director Theodore R. Samuels II purchased 6,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the purchase, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.23% of the company’s stock.

Several large investors have recently bought and sold shares of BMY. Renaissance Technologies LLC raised its stake in Bristol-Myers Squibb by 108.5% in the second quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after buying an additional 7,020,200 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Bristol-Myers Squibb by 185.2% in the second quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after buying an additional 3,960,191 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Bristol-Myers Squibb by 2,990.5% in the second quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after buying an additional 3,516,536 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Bristol-Myers Squibb by 42,071.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after buying an additional 3,323,649 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after buying an additional 2,451,390 shares during the last quarter. Institutional investors own 68.78% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Sees Unusually High Options Volume (BMY)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/03/bristol-myers-squibb-sees-unusually-high-options-volume-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.